罗米司亭在成人临床试验与全球上市后登记中的免疫原性评估
该分析评估了13项临床试验和全球上市后登记中成人免疫性血小板减少症(ITP)患者对罗米司亭或TPO的抗体产生情况。无患者产生抗TPO中和抗体。
要点
- 中和抗体与罗米司亭剂量无关,且未影响血小板计数反应。
- 无患者产生抗TPO中和抗体,未见与TPO交叉反应。
核心结论
- 抗罗米司亭结合抗体产生不频繁,中和抗体罕见且不与TPO交叉反应,不伴随血小板反应丢失。
研究设计与样本
- 分析13项临床试验和一项全球上市后登记中成人ITP患者。
- 临床试验共961例患者,上市后登记自发送检样本184例。
主要发现
- 首次结合抗体阳性中位时间为开始罗米司亭后14周,中位剂量2 µg/kg,中位血小板计数29.5×10^9/l。
临床怎么用
- 罗米司亭免疫原性低,中和抗体罕见且多无临床影响,无需常规抗体监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibodies to first-generation recombinant thrombopoietin (TPO) neutralized endogenous TPO and caused thrombocytopenia in some healthy subjects and chemotherapy patients. The second-generation TPO receptor agonist romiplostim, having no sequence homology to TPO, was developed to avoid immunogenicity. This analysis examined development of binding and neutralising antibodies to romiplostim or TPO among adults with immune thrombocytopenia (ITP) in 13 clinical trials and a global postmarketing registry. 60/961 (6·2%) patients from clinical trials developed anti-romiplostim-binding antibodies post-baseline. The first positive binding antibody was detected 14 weeks (median) after starting romiplostim, at median romiplostim dose of 2 µg/kg and median platelet count of 29.5 × 109 /l; most subjects had ≥98·5% of platelet assessments showing response. Neutralising antibodies to romiplostim developed in 0·4% of patients, but were unrelated to romiplostim dose and did not affect platelet count. Thirty-three patients (3·4%) developed anti-TPO-binding antibodies; none developed anti-TPO-neutralising antibodies. In the global postmarketing registry, 9/184 (4·9%) patients with spontaneously submitted samples had binding antibodies. One patient with loss of response had anti-romiplostim-neutralising antibodies (negative at follow-up). Collectively, anti-romiplostim-binding antibodies developed infrequently. In the few patients who developed neutralising antibodies to romiplostim, there was no cross-reactivity with TPO and no associated loss of platelet response.
引用
- Mytych DT, Park JK, Kim J, et al. Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry. Br J Haematol. 2020. PMID: 32311075. doi:10.1111/bjh.16658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。